Monoclonal antibody therapies against SARS-CoV-2
The Lancet Infectious Diseases, 2022•thelancet.com
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs
and their effect as therapeutics in the pandemic, including structural classification, outcomes
in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent
immune escape. We show how the omicron (B. 1.1. 529) variant of concern has reset
treatment strategies so far, discuss future developments that could lead to improved …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs
and their effect as therapeutics in the pandemic, including structural classification, outcomes
in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent
immune escape. We show how the omicron (B. 1.1. 529) variant of concern has reset
treatment strategies so far, discuss future developments that could lead to improved …
Summary
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent immune escape. We show how the omicron (B.1.1.529) variant of concern has reset treatment strategies so far, discuss future developments that could lead to improved outcomes, and report the intrinsic limitations of using mAbs as therapeutic agents.
thelancet.com
